Robert Gil

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6722014/publications.pdf

Version: 2024-02-01

77	2,249	304743 22	233421 45
papers	citations	h-index	g-index

79	79	79	2429
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ultrastructural Changes in Mitochondria in Patients with Dilated Cardiomyopathy and Parvovirus B19 Detected in Heart Tissue without Myocarditis. Journal of Personalized Medicine, 2022, 12, 177.	2.5	4
2	Which patients at risk of cardiovascular disease might benefit the most from inclisiran? â€“ The expert opinion of the Polish experts. The compromise between EBM and possibilities in healthcare.. Archives of Medical Science, 2022, 18, 569-576.	0.9	9
3	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 707-716.	3.0	5
4	Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022. Cardiology Journal, 2022, 29, 540-552.	1.2	3
5	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. JACC: Cardiovascular Interventions, 2021, 14, 444-456.	2.9	27
6	Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients â€“ propensity-score matched case-control study. International Journal of Infectious Diseases, 2021, 105, 209-215.	3.3	29
7	A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiology Journal, 2021, 28, 607-614.	1.2	3
8	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. European Heart Journal, 2021, 42, 4683-4693.	2.2	18
9	Feasibility and safety of the new coronary noncompliant balloon catheter River NCÂ®. Future Cardiology, 2021, 17, 1123-1130.	1.2	1
10	Long-Term Outcomes Following Drug-Eluting Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis (DEB-Dragon-Registry). Circulation: Cardiovascular Interventions, 2021, 14, e010868.	3.9	9
11	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European Heart Journal, 2021, 42, 4624-4634.	2.2	54
12	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal, 2020, 41, 3533-3545.	2.2	93
13	Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies. Cardiovascular Therapeutics, 2020, 2020, 1-8.	2.5	6
14	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiology Journal, 2020, 27, 661-676.	1.2	7
15	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	27.0	683
16	Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAl arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial). American Heart Journal, 2019, 214, 107-112.	2.7	1
17	Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society. Cardiology Journal, 2019, 26, 1-7.	1.2	5
18	Impact of Routine Invasive Physiology atÂTime of Angiography in Patients WithÂMultivessel Coronary Artery DiseaseÂon Reclassification of Revascularization Strategy. JACC: Cardiovascular Interventions, 2018, 11, 354-365.	2.9	24

#	Article	IF	Citations
19	Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up. International Journal of Cardiovascular Imaging, 2018, 34, 353-365.	1.5	11
20	Advances in Mechanisms and Treatment Options of MINOCA Caused by Vasospasm or Microcirculation Dysfunction. Current Pharmaceutical Design, 2018, 24, 517-531.	1.9	9
21	Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies. Cardiology Journal, 2018, 25, 308-316.	1.2	7
22	Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated expertsâ€™ standpoint. Cardiology Journal, 2018, 25, 291-300.	1.2	18
23	Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study. Cardiology Journal, 2018, 25, 188-195.	1.2	1
24	Rotational atherectomy in everyday clinical practice. Association of Cardiovascular Interventions of the Polish Society of Cardiology (Asocjacja Interwencji Sercowo-Naczyniowych Polskiego) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 537 Td (	0.6	10
25	BiOSS LIM C: thin-strut cobalt-chromium version of the dedicated bifurcation stent. Expert Review of Medical Devices, 2017, 14, 279-284.	2.8	3
26	Assessment of vascular response to Bi<scp>OSS LIM</scp> C^{Â®} stents vs Orsiro^{Â®} stents in the porcine coronary artery model. Cardiovascular Therapeutics, 2017, 35, e12267.	2.5	6
27	Platelet distribution width as the prognostic marker in coronary bifurcation treatment. European Journal of Clinical Investigation, 2017, 47, 524-530.	3.4	13
28	The approach to coronary bifurcation treatment and its outcomes in Poland: The single center experience. Cardiology Journal, 2017, 24, 589-596.	1.2	1
29	Transcatheter aortic valve implantation. Expert Consensus of the Association of Cardiovascular Interventions of the Polish Cardiac Society and the Polish Society of Cardio-Thoracic Surgeons, approved by the Board of the Polish Cardiac Societyâ€¦. Kardiologia Polska, 2017, 75, 937-964.	0.6	7
30	Anti-aggregation therapy in patients with acute coronary syndrome â€" recommendations for medical emergency teams. Expertsâ€™ standpoint. Kardiologia Polska, 2017, 75, 399-408.	0.6	5
31	Temporal healing patterns and coverage dynamics after new Polish transcatheter PFO occluder implantation in a swine. Kardiologia Polska, 2017, 75, 907-913.	0.6	1
32	Anti-aggregation therapy in patients with acute coronary syndrome â€" recommendations for medical emergency teams. Expertsâ€™ standpoint. Kardiologia Polska, 2017, 75, 47-56.	0.6	0
33	Circulatory support with Impella CP device during high-risk percutaneous coronary interventions: initial experience in Poland. Postepy W Kardiologii Interwencyjnej, 2016, 3, 254-257.	0.2	6
34	Bioresorbable vascular scaffoldsâ€"what does the future bring?. Journal of Thoracic Disease, 2016, 8, E741-E745.	1.4	13
35	The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review. Advances in Medical Sciences, 2016, 61, 331-343.	2.1	21
36	12-month intravascular ultrasound observations from BiOSSÂ® first-in-man studies. International Journal of Cardiovascular Imaging, 2016, 32, 1339-1347.	1.5	2

#	Article	IF	Citations
37	Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIMÂ® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry. EuroIntervention, 2016, 12, 1246-1254.	3.2	12
38	Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIMÂ® stent: the randomised, multicentre, open-label, controlled POLBOS II trial. EuroIntervention, 2016, 12, e1404-e1412.	3.2	27
39	Firstâ€inâ€Man Study of Dedicated Bifurcation Sirolimusâ€eluting Stent: 12â€month Results of BiOSS LIMÂ® Registry. Journal of Interventional Cardiology, 2015, 28, 51-60.	1.2	17
40	Coronary spasm revascularized with a bioresorbable vascular scaffold. Coronary Artery Disease, 2015, 26, 634-636.	0.7	5
41	Impella LD microaxial pump supporting combined mitral and coronary surgery in a patient with dilated cardiomyopathy. A short bridge to recovery?. Kardiochirurgia I Torakochirurgia Polska, 2015, 1, 56-59.	0.1	1
42	Patient with ST-elevation myocardial infarction, coronary artery embolism and no signs of coronary atherosclerosis in angiography. Postepy W Kardiologii Interwencyjnej, 2015, 4, 334-336.	0.2	1
43	Aneurysm formation after paclitaxel-eluting balloon angioplasty used to treat coronary artery restenosis after plain old balloon angioplasty â€“ case report and review of the literature. Postepy W Kardiologii Interwencyjnej, 2015, 3, 250-251.	0.2	3
44	Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial. Canadian Journal of Cardiology, 2015, 31, 671-678.	1.7	22
45	Dedicated stents for distal left main stenting. EuroIntervention, 2015, 11, V129-V134.	3.2	9
46	Dedicated Bifurcation Paclitaxelâ€Eluting Stent BiOSS ExpertÂ® in the Treatment of Distal Left Main Stem Stenosis. Journal of Interventional Cardiology, 2014, 27, 242-251.	1.2	26
47	Comparative analysis of lumen enlargement mechanisms achieved with the bifurcation dedicated BiOSSÂ® stent versus classical coronary stent implantations by means of provisional side branch stenting strategy: an intravascular ultrasound study. International Journal of Cardiovascular Imaging, 2013, 29, 1667-1676.	1.5	15
48	Optical coherence tomography criteria for defining functional severity of intermediate lesions: a comparative study with FFR. International Journal of Cardiovascular Imaging, 2013, 29, 1685-1691.	1.5	38
49	Assessment of Clinical, Electrocardiographic, and Physiological Relevance of Diagonal Branch in Left Anterior Descending Coronary Artery Bifurcation Lesions. JACC: Cardiovascular Interventions, 2012, 5, 1126-1132.	2.9	22
50	Bifurcation Optimisation Stent System (BiOSS Lim) with sirolimus elution: results from porcine coronary artery model. EuroIntervention, 2011, 7, 614-620.	3.2	15
51	Extension Distance Mismatchâ€"An Unrecognized Factor for Suboptimal Side Branch Ostial Coverage in Bifurcation Lesion Stenting. Journal of Interventional Cardiology, 2010, 23, 305-318.	1.2	6
52	A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. European Heart Journal, 2009, 30, 1590-1597.	2.2	83
53	Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: A prospective multicenter registry. Catheterization and Cardiovascular Interventions, 2008, 71, 51-57.	1.7	30
54	Intravascular ultrasound guidance may be an option for coronary interventions. Catheterization and Cardiovascular Interventions, 2008, 72, 750-751.	1.7	0

#	Article	IF	Citations
55	Ulnar Artery as Access Site for Cardiac Catheterization: Anatomical Considerations. Journal of Interventional Cardiology, 2008, 21, 56-60.	1.2	28
56	Clinical Verification of a Theory for Predicting Side Branch Stenosis after Main Vessel Stenting in Coronary Bifurcation Lesions. Journal of Interventional Cardiology, 2008, 21, 493-503.	1.2	49
57	Transient left apical ballooning syndromeâ€"The need for common terminology?. International Journal of Cardiology, 2008, 131, 138-139.	1.7	3
58	Heparin-Coated Stent Placement for the Treatment of Stenoses in Small Coronary Arteries of Symptomatic Patients. Circulation, 2003, 107, 1265-1270.	1.6	87
59	Stenting of Culprit Lesions in Unstable Angina Leads to a Marked Reduction in Plaque Burden: A Major Role of Plaque Embolization?. Circulation, 2003, 107, 2320-2325.	1.6	95
60	Balloon positioning difficulties during nonsurgical septal reduction therapy in a patient with hypertrophic obstructive cardiomyopathy. Catheterization and Cardiovascular Interventions, 2000, 49, 314-317.	1.7	2
61	A randomized comparison of elective high-pressure stenting with balloon angioplasty: Six-month angiographic and two-year clinical follow-up. American Heart Journal, 2000, 140, 264-271.	2.7	15
62	Long-Term Restenosis After Multiple Stent Implantation: A Quantitative Angiographic Study. Journal of Interventional Cardiology, 1997, 10, 287-293.	1.2	0
63	Ultrasound-guided treatment of acute coronary stent thrombosis. American Heart Journal, 1996, 132, 1081-1084.	2.7	2
64	Optimized expansion of the Wallstent compared with the Palmaz-Schatz stent: On-line observations with two- and three-dimensional intracoronary ultrasound after angiographic guidance. American Heart Journal, 1996, 131, 1067-1075.	2.7	48
65	Influence of plaque composition on mechanisms of percutaneous transluminal coronary balloon angioplasty assessed by ultrasound imaging. American Heart Journal, 1996, 131, 591-597.	2.7	10
66	Impact of plaque morphology and composition on the mechanisms of lumen enlargement using intracoronary ultrasound and quantitative angiography after balloon angioplasty. American Journal of Cardiology, 1996, 77, 115-121.	1.6	55
67	Usefulness of three-dimensional reconstruction for interpretation and quantitative analysis of intracoronary ultrasound during stent deployment. American Journal of Cardiology, 1996, 77, 761-764.	1.6	27
68	Usefulness of on-line three-dimensional reconstruction of intracoronary ultrasound for guidance of stent deployment. American Journal of Cardiology, 1996, 77, 455-461.	1.6	25
69	Quantification of the minimal luminal cross-sectional area after coronary stenting by two-and three-dimensional intravascular ultrasound versus edge detection and videodensitometry. American Journal of Cardiology, 1996, 78, 520-525.	1.6	62
70	Utilization of translesional hemodynamics: Comparison of pressure and flow methods in stenosis assessment in patients with coronary artery disease. , 1996, 38, 189-201.		29
71	Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. American Journal of Cardiology, 1995, 75, 772-777.	1.6	143
72	Long-term reproducibility of coronary flow velocity measurements in patients with coronary artery disease. American Journal of Cardiology, 1995, 75, 1177-1180.	1.6	30

#	Article	IF	Citations
73	Perforation of chronic total occlusion with laser guide wire followed by multiple stent deployment: Usefulness of three-dimensional intracoronary ultrasound guidance. American Heart Journal, 1995, 130, 1286-1289.	2.7	2
74	Mechanism of high-speed rotational atherectomy and adjunctive balloon angioplasty revisited by quantitative coronary angiography: Edge detection versus videodensitometry. American Heart Journal, 1995, 130, 405-412.	2.7	10
75	901-20 Usefulness of On-line 3D Reconstruction for Stent Implantation. Journal of the American College of Cardiology, 1995, 25, 9A-10A.	2.8	4
76	Response of conductance and resistance coronary vessels to scalar concentrations of acetylcholine: Assessment with quantitative angiography and intracoronary doppler echography in 29 patients with coronary artery disease. American Heart Journal, 1994, 127, 514-531.	2.7	20
77	Maximal blood flow velocity in severe coronary stenoses measured with a Doppler guidewire. American Journal of Cardiology, 1993, 71, D54-D61.	1.6	55